ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)
Study Status
Closed to Enrollment
Study Description
The purpose of this study is to compare the disease-free survivial of patients with locally advanced renal cell carciinoma (kidney cancer) treated with adjuvant sunitinib male vs sorafenib vs placebo after a radical or partial nephrectomy (kidney removal).
Patients will be randomized to either:
- Arm A: Sunitinib
- Arm B: sorafenib alone
- Arm C: placebo
Disease Status and/or Stage
Renal Cell Cancer
Sponsor
Eastern Cooperative Oncology Group
Key Eligibility
- Must have primary intact RCC, eligible for nephrectomy with curative intent
- No prior anti-cancer therapy is permitted in either the adjuvant or neoadjuvant setting. This includes metastectomy for renal cell carcinoma or radiation therapy to the renal bed
- Additional eligibility discussed when you contact the study team
Principal Investigator
Contact
- Gina Mileo, RN
- 212-746-5430
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]